Selecta Biosciences
Signal active
Investment Firm
Overview
Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles.
It was founded in 2008 and is headquartered in Watertown, Massachusetts.
Highlights
Founded
2008
Industry
Biotechnology
Employees
51-100
Investment
1
Lead Investment
0
Exits
undefined
Stages
Early Stage Venture
Investor Type
N/A
Location
United States, North America
Contact Information
Social
Profile Resume
Selecta Biosciences, established in 2008 and headquartered in United States, North America., specializes in Early Stage Venture investments across Software, Biotechnology, Nutrition, Venture Capital, Finance, AgTech, Health Care, Advanced Materials, Health Diagnostics, Financial Services. Their recent investments include Cyrus Biotechnology, Trinity Ventures, iSelect Fund, OrbiMed, Washington Research Foundation. The highest investment round they participated in was $1.5B. Among their most notable exits are Cyrus Biotechnology and Trinity Ventures. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
Selecta Biosciences has made 1 diversity investments. Their most recent diversity investment was on Dec 06, 2021, when Cyrus Biotechnology raised $18.0M.
investments
1
Diversity investments
1
Lead investments
0
Number of exits
undefined
Investments
1
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Dec 06, 2021 | Cyrus Biotechnology | Software | 18.0M |
Cyrus BiotechnologyExits
0
Funding Timeline
Funding rounds
1
Investors
20
Funds
0
Funding Rounds
1
Selecta Biosciences has raised 1 rounds. Their latest funding was raised on Dec 06, 2021 from a Series B - Cyrus Biotechnology round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Dec 06, 2021 | Series B - Cyrus Biotechnology | - | 18.0M | - |
Investors
47
Selecta Biosciences is funded by 47 investor(s). Silicon Valley Bank and Oxford Finance LLC Kantor are the most recent investors.
| Investor Name | Lead Investor | Funding Round | Money Raised |
|---|---|---|---|
Oxford Finance LLC | No | Post-IPO Debt - Selecta Biosciences | 35.0M |
Silicon Valley Bank | No | Post-IPO Debt - Selecta Biosciences | 35.0M |
| - | No | Post-IPO Equity - Selecta Biosciences | 38.7M |
| - | No | Post-IPO Equity - Selecta Biosciences | 60.3M |
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.